Henry M Jackson Foundation For The Advancement Of Military Medicine Licenses Herpes Virus Vaccine Technology for Advanced Development

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

October 20, 2020

Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) and Citranvi Biosciences (Citranvi), a company led by former vaccine developers and scientists from top pharmaceutical companies, have signed an exclusive licensing agreement to develop vaccine technologies to prevent Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) infections.

Research for these technologies was conducted by DoD researchers at the Uniformed Services University of the Health Sciences (USU) and patented by the Henry M. Jackson Foundation under the USU-HJF Joint Office of Technology Transfer.

“The dangers posed by congenital CMV and EBV are significant,” said Dr. Krishna Prasad, Founder of Citranvi Biosciences, based in North Carolina. “Citranvi is excited to partner with HJF toward the goal of developing vaccines.”

CMV has a significant maternal-to-infant infection rate and is the most common infectious cause of brain damage and sensorineural hearing loss in infants. Nearly 30%–40% of adolescents who contract EBV will develop infectious mononucleosis, which can lead to serious complications such as liver failure, splenic rupture, and hematologic disorders. EBV is also linked with an increased risk for autoimmunity and nearly 140,000 cancer deaths annually. Infections due to CMV and EBV pose significant risks for transplant patients.

The technology can be used to produce recombinant proteins in a multimeric form, thereby increasing the ability of the vaccines to generate protective antibodies.

“Herpesviruses can impact anyone, even warfighters. Consequently, they pose a risk to force readiness,” said HJF President and CEO, Dr. Joseph Caravalho. “HJF’s mission is to advance military medicine and part of that mandate is ensuring our nation’s warfighters are healthy and able to fulfill their mission. The hope is that this partnership with Citranvi will lead to a new vaccine to fight EBV and CMV, ultimately improving force readiness and benefiting warfighters and civilians alike.”

Research for these technologies was conducted at The Uniformed Services University of the Health Sciences (USU). This research was sponsored by USU; however, the information or content and conclusions do not necessarily represent the official position or policy of, nor should any official endorsement be inferred on the part of, USU, the Department of Defense, or the U.S. Government.

The project described was supported by Grant Number 1R21AI073627 from the National Institute of Allergy and Infectious Disease. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Disease or the National Institutes of Health.

 

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles